Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Can-Fite completes patient enrollment in phase II CF-101 dry eye syndrome trial

Jan. 29, 2009

Inspire initiates phase III Prolacria trial under FDA special protocol

Jan. 28, 2009

FDA accepts Sirion's ganciclovir NDA for review for treatment of ocular herpes

Jan. 27, 2009

ISTA reports positive phase IIb ecabet sodium trial results

Jan. 23, 2009

EMEA grants Premacure orphan designation for Insmed's Iplex in infant ROP

Jan. 23, 2009

RegeneRx presents update on clinical development of RGN-259 for nonhealing corneal ulcers

Jan. 22, 2009

Xoma provides guidance update for 2008

Jan. 22, 2009

FDA accepts for review ISTA's NDA for Bepreve for allergic conjunctivitis

Jan. 19, 2009

FDA approves Alcon's IND application for NovaBay's NVC-422 for eye infections

Jan. 19, 2009

MacuCLEAR and Mystic collaborate on macular degeneration phase I/II trial

Jan. 15, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.